查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858224

RSV診斷市場依檢測類型、產品、技術平台、最終用戶、檢體類型、通路和年齡層別分類－全球預測（2025-2032年）

RSV Diagnostics Market by Test Type, Product, Technology Platform, End User, Sample Type, Distribution Channel, Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，RSV 診斷市場將成長至 24 億美元，複合年成長率為 9.37%。

關鍵市場統計數據
基準年 2024 11.7億美元
預計年份：2025年 12.8億美元
預測年份 2032 24億美元
複合年成長率 (%) 9.37%

對呼吸道合胞病毒（RSV）診斷優先事項、技術融合、臨床效用、影響醫療機構檢測採用的運作因素進行全面分析

本執行摘要摘要了呼吸道融合細胞病毒(RSV) 診斷的最新趨勢，綜合分析了對檢查室主任、臨床負責人和產品負責人至關重要的臨床、技術和商業性發展動態。 RSV 診斷已從疫情驅動的重點領域轉變為呼吸道疾病管理的重要組成部分，這得益於監測手段的改進、就地檢驗能力的提升以及臨床指南的不斷完善。實施過程體現了臨床必要性。及時且準確的檢測結果有助於指導治療決策、機構隔離和公共衛生應對措施。本報告還提供了一個分析方法框架，重點關注診斷路徑、技術實施、產品生態系統和最終用戶需求。

技術融合、分散式檢測能力和不斷發展的臨床工作流程將如何重塑呼吸道合胞病毒（RSV）的診斷和治療路徑決策

呼吸道合胞病毒（RSV）的診斷格局正在經歷變革，這主要得益於技術創新、臨床實踐的改變以及系統層面提高呼吸道病原體快速檢測能力的迫切需求。分子診斷平台正從集中式檢查室轉移到更貼近患者的分散式機構，實現更早期的檢測和更有針對性的臨床干預。同時，化學冷光和螢光免疫檢測分析靈敏度的提升正在縮小速度和準確性之間的差距。等溫擴增技術和改進的側向流動化學方法的應用代表了更廣泛的趨勢。曾經因安裝環境而分散的各種技術正在融合，以滿足不同應用場景的需求。

評估2025年美國關稅調整對供應鏈韌性、籌資策略和診斷連續性的累積營運影響

2025年美國關稅調整和貿易政策變化對整個診斷供應鏈產生了連鎖反應，影響了儀器、試劑盒和試劑的籌資策略、採購決策和成本結構。製造商和經銷商的零件採購方式發生了變化，促使他們重新評估供應商組合，並加快關鍵零件（如分析儀、PCR儀、緩衝液和酵素）的近岸外包。因此，採購團隊更重視供應商多元化和合約彈性，以降低未來貿易相關干擾的影響。

整合細分分析以指導策略重點：將測試類型、產品生態系統、技術平台、終端用戶環境、檢體類型、分銷管道和患者人口統計資訊連結起來

嚴謹的細分分析識別出呼吸道合胞病毒（RSV）診斷領域中價值和風險集中的區域。按檢測類型分類，免疫檢測、分子檢測和快速檢測在性能和應用方面有顯著差異。免疫檢測可再細分為化學冷光免疫檢測、酵素免疫分析法及免疫螢光法法。分子檢測進一步分為等溫擴增、次世代定序和即時聚合酵素鏈鎖反應，而快速檢測則根據橫向流動化驗和微流體控技術進行區分。每個子類別在通量、靈敏度和照護現場適用性方面都存在獨特的權衡，這凸顯了檢查室和臨床醫生應優先投資的領域。

美洲、歐洲、中東和非洲以及亞太地區的區域診斷重點和操作實踐將決定部署路徑和供應策略。

區域趨勢影響診斷重點、報銷政策和營運限制，直接影響技術採納和部署策略。在美洲，臨床網路和醫院系統優先考慮整合的檢查室工作流程和快速獲取確診性分子檢測，而門診診所和社區醫療機構則擴大採用就地檢驗。製造商正致力於開發可擴展的儀器平台以及相容的試劑盒和試劑，以支持不同臨床層面的廣泛應用。

診斷試劑製造商和專業供應商如何協調平台策略、夥伴關係和供應鏈能力，以加速臨床應用並支援多元化的終端用戶

領先的診斷公司和專業供應商持續利用平台優勢和策略夥伴關係關係，推動呼吸道合胞病毒（RSV）檢查室，並簡化採購流程。與學術機構和臨床網路進行策略合作，將有助於檢驗工作，並在監管允許的情況下加速臨床應用。

為診斷產業領導者提供實際的策略行動，以增強供應鏈韌性、檢驗臨床效能，並使產品適應不同的臨床環境和使用者需求。

產業領導者應優先採取一系列切實可行的措施，將診斷科學轉化為持續的臨床影響和商業性可行性。首先，透過多元化組件採購和協商能夠適應關稅波動和物流中斷的靈活契約，增強供應鏈的韌性。其次，投資於與學術和醫院檢查室的檢驗夥伴關係，以產生關鍵檢體類型（例如鼻咽拭子和唾液）的獨立表現數據，並證明其在成人、老年人和兒童群體中的臨床效用。這些合作將有助於促進臨床認可，並為醫保報銷談判奠定基礎。

透明的多來源調查方法，結合文獻綜述、監管審查、技術檢驗和相關人員訪談，可提供嚴謹的診斷見解和清晰的細分。

本研究整合了同行評審文獻、監管申報文件、臨床指南文件、產品技術規範以及對關鍵相關利益者的訪談，從而構建了呼吸道合胞病毒（RSV）診斷的多維度視角。調查方法結合了近期科學文章和技術白皮書的系統性回顧，以及檢查室主任、臨床終端使用者和產業專家的結構化訪談。分析重點在於利用獨立報告的效能數據和實際應用回饋對技術聲明進行交叉檢驗。

診斷技術優勢、營運需求和策略重點的整合將決定呼吸道合胞病毒（RSV）檢測在臨床和商業性的持續成功。

總之，呼吸道合胞病毒（RSV）診斷格局取決於技術能力與實際應用之間的動態平衡。分子診斷、免疫檢測分析和快速檢測方法各自為臨床路徑帶來獨特的優勢，它們的融合為透過更快、更準確的檢測來改善患者預後創造了機會。供應鏈和貿易趨勢凸顯了建構彈性採購和靈活營運規劃的必要性，而不同地區和終端用戶的多樣性則要求產品設計和商業化採取量身定做的方法。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • RSV的快速分子檢測正在迅速普及，從而實現分散式患者管理和快速治療決策。
  • 利用整合了呼吸道合胞病毒 (RSV)、流感病毒和 SARS-CoV-2 檢測的多重呼吸道病毒檢測板，進行全面的季節性病毒監測
  • 採用等溫擴增技術可提高門診檢測的敏感度並縮短檢測週轉時間
  • 遠端醫療平台和遠端患者監護解決方案推動了家用呼吸道合胞病毒檢測套組的需求。
  • 本院加強對兒童和新生兒呼吸道合胞病毒篩檢通訊協定的重視，旨在降低嚴重感染率並最佳化資源分配。
  • 數位醫療和人工智慧驅動的分析工具的出現，提高了呼吸道合胞病毒診斷檢查室的準確性和工作流程效率。
  • 臨床試驗中用於呼吸道合胞病毒基因分型和抗病毒抗藥性分析的次世代定序檢測獲得監管部門核准
  • 新冠感染疾病後呼吸道合胞病毒季節性模式變化對檢測量及公共衛生監測策略的影響

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. RSV診斷市場按檢測類型分類

  • 免疫檢測
    • 化學冷光免疫檢測
    • 酵素免疫分析法
    • 螢光
  • 分子檢測
    • 等溫擴增
    • 次世代定序
    • 即時聚合酵素鏈鎖反應
  • 快速檢測
    • 橫向流動化驗
    • 微流體檢測

9. RSV診斷產品市場

  • 裝置
    • 分析器
    • PCR裝置
  • 成套工具
    • 唾液採集套裝
    • 拭子採集套裝
  • 試劑
    • 緩衝溶液
    • 酵素

10. 依技術平台分類的呼吸道合胞病毒 (RSV) 診斷市場

  • ELISA
  • 螢光
  • PCR

第11章 RSV 診斷市場（按最終用戶分類）

  • 學術機構
  • 診所
  • 診斷檢查室
  • 居家照護
  • 醫院檢查室

第12章：依檢體類型分類的呼吸道合胞病毒（RSV）診斷市場

  • 血
  • 鼻咽拭子
  • 唾液

第13章 RSV診斷市場（依通路分類）

  • 離線
  • 線上

第14章 依年齡層別分類的呼吸道合胞病毒（RSV）診斷市場

  • 成人
  • 老年人
  • 兒童

第15章 區域性呼吸道合胞病毒（RSV）診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 RSV診斷市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國呼吸道合胞病毒診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • Roche Diagnostics International AG
    • QuidelOrtho Corporation
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Becton, Dickinson and Company
    • Danaher Corporation
    • Meridian Bioscience, Inc.
    • DiaSorin SpA
    • QIAGEN NV
Product Code: MRR-C002B1C99841

The RSV Diagnostics Market is projected to grow by USD 2.40 billion at a CAGR of 9.37% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.17 billion
Estimated Year [2025] USD 1.28 billion
Forecast Year [2032] USD 2.40 billion
CAGR (%) 9.37%

Comprehensive framing of RSV diagnostic priorities, technology convergence, clinical utility, and the operational levers that influence testing adoption across care settings

This executive summary distills current dynamics in diagnostics for respiratory syncytial virus, synthesizing clinical, technological, and commercial developments that matter for laboratory directors, clinical strategists, and product leaders. Diagnostics for RSV have moved from episodic pandemic-driven attention to an integrated element of respiratory disease management, informed by improved surveillance, expanded point-of-care capabilities, and evolving clinical guidelines. The introduction establishes the clinical imperative: timely, accurate testing informs therapeutic decisions, cohorting in institutions, and public health responses. It also frames the analytical approach used in the report, which emphasizes diagnostic pathways, technology adoption, product ecosystems, and end-user needs.

Building on that foundation, the introduction highlights the intersection of new molecular modalities, advanced immunoassays, and rapid formats that together broaden diagnostic accessibility. The report places equal emphasis on instruments, kits, and reagents as interdependent components of diagnostic deployment, and on the distribution and sample collection systems that enable real-world use. Finally, the introduction previews strategic themes explored in depth: how technology convergence, regulatory shifts, and reimbursement dynamics are reshaping testing practice across a wide set of clinical and non-clinical settings.

How technological convergence, decentralization of testing capabilities, and evolving clinical workflows are reshaping RSV diagnostics and care pathway decisions

The diagnostics landscape for RSV is undergoing transformative shifts driven by technological innovation, changing clinical practice, and system-level imperatives to improve rapid respiratory pathogen detection. Molecular platforms have migrated from centralized laboratories toward near-patient and decentralized settings, enabling earlier detection and more targeted clinical action. At the same time, immunoassays have improved analytic sensitivity through chemiluminescence and immunofluorescence approaches, narrowing the gap between rapidity and accuracy. Adoption of isothermal amplification and refined lateral flow chemistries illustrates a broader trend: technologies once siloed by setting are converging to meet diverse use-case requirements.

Concurrently, end-user expectations and care pathways are evolving. Hospitals and diagnostic laboratories increasingly integrate multiplexed testing strategies to differentiate RSV from other respiratory pathogens, while clinics and home care settings prioritize user-friendly rapid tests that support quick triage. Academic institutes continue to drive validation studies and novel assay development, whereas commercial entities accelerate scale-up of instruments, kits, and reagents to support distributed testing networks. These shifts are reinforced by an emphasis on standardized sample types such as nasopharyngeal swabs and saliva, which facilitate easier collection and broader testing accessibility. Together, these dynamics are reshaping how diagnostics are developed, validated, and delivered across the continuum of care.

Assessment of the cumulative operational effects of United States tariff adjustments in 2025 on supply chain resilience, procurement strategy, and diagnostic continuity

Tariff adjustments and trade policy changes implemented in the United States in 2025 created a ripple effect across diagnostic supply chains, influencing procurement strategies, sourcing decisions, and cost structures for instruments, kits, and reagents. Manufacturers and distributors experienced shifts in component sourcing, prompting a reevaluation of supplier portfolios and an acceleration of nearshoring initiatives for critical items such as analyzers, PCR machines, buffers, and enzymes. As a result, procurement teams began to place greater emphasis on supplier diversification and contractual flexibility to mitigate future trade-related disruptions.

In response, several diagnostic firms adjusted manufacturing footprints and logistics pathways to preserve service continuity for clinics, hospital laboratories, and diagnostic labs. These adjustments affected how products reached end users through both offline and online channels, with distributors optimizing inventory allocation across regions. The tariffs also encouraged stronger collaboration between instrument vendors and kit and reagent suppliers, given the interdependence of analyzers, PCR machines, saliva collection kits, swab collection kits, and reagent supplies. Overall, the 2025 tariff environment reinforced the importance of supply chain resilience and contractual agility in sustaining diagnostic availability and minimizing disruptions to clinical testing programs.

Integrated segmentation analysis linking test types, product ecosystems, technology platforms, end-user settings, sample types, distribution channels, and patient age cohorts to guide strategic focus

A rigorous segmentation lens clarifies where value and risk concentrate across the RSV diagnostics space. By test type, distinctions among immunoassay, molecular test, and rapid test categories reveal distinct performance and deployment profiles, with immunoassays further differentiated by chemiluminescence immunoassay, enzyme linked immunosorbent assay, and immunofluorescence assay modalities; molecular tests further divided into isothermal amplification, next generation sequencing, and real time polymerase chain reaction methods; and rapid tests differentiated across lateral flow assay and microfluidic assay formats. Each of these subcategories presents unique trade-offs in throughput, sensitivity, and point-of-care suitability, informing where laboratories and clinicians prioritize investment.

Examining products clarifies ecosystem dependencies among instruments, kits, and reagents, with analyzers and PCR machines serving as foundational hardware, saliva and swab collection kits defining preanalytical workflows, and buffers and enzymes enabling core assay chemistry. The technology platform perspective, which includes ELISA, immunofluorescence, and PCR, highlights the technical approaches that underpin assay performance and regulatory pathways. End-user segmentation spans academic institutes, clinics, diagnostic laboratories, home care, and hospital laboratories, reflecting varying operational demands and purchasing processes. Sample type distinctions among blood, nasopharyngeal swab, and saliva influence both clinical acceptance and logistics, while distribution channels across offline and online paths determine accessibility and time-to-result. Age group segmentation across adult, geriatric, and pediatric populations further refines clinical use cases and regulatory considerations. Taken together, these lenses enable decision-makers to align product development, distribution strategies, and validation efforts with real-world diagnostic needs.

Regional diagnostic priorities and operational realities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption pathways and supply strategies

Regional dynamics shape diagnostic priorities, reimbursement realities, and operational constraints in ways that directly influence technology adoption and deployment strategies. In the Americas, clinical networks and hospital systems prioritize integrated laboratory workflows and rapid access to confirmatory molecular testing, while point-of-care adoption grows in outpatient clinics and community health settings. Manufacturers focus on scalable instrument platforms and compatible kits and reagents to support broad adoption across different clinical tiers.

In Europe, the Middle East & Africa, regulatory harmonization efforts and varying reimbursement environments create a heterogeneous landscape where decentralization gains traction in some markets while centralized laboratory testing remains dominant in others. Investment in sample collection systems and cold chain logistics is a recurring regional priority. In Asia-Pacific, high-volume diagnostic networks, rapid technology uptake, and strong manufacturing capabilities accelerate availability of diverse test formats, from high-throughput analyzers to rapid lateral flow assays and microfluidic solutions. Across regions, distribution channels and age group considerations influence how suppliers tailor product bundles and support services to meet local clinical and operational needs.

How diagnostic manufacturers and specialized suppliers are aligning platform strategies, partnerships, and supply chain capabilities to accelerate clinical adoption and support diverse end users

Leading diagnostic companies and specialized suppliers continue to drive innovation and operational scale in the RSV testing landscape, leveraging platform advantages and strategic partnerships to expand reach. Key players concentrate on strengthening their instrument ecosystems while ensuring compatibility with a broad range of kits and reagents, thereby lowering barriers for laboratory integration and enabling smoother procurement cycles. Strategic collaborations with academic institutes and clinical networks support validation efforts and expedite clinical adoption where regulatory pathways allow.

Commercial strategies increasingly emphasize after-sales support, assay validation services, and digital enablement to link test results to care pathways. Firms that invest in robust quality systems, regulatory expertise, and resilient supply chains position themselves to serve hospitals, diagnostic laboratories, clinics, and home care settings effectively. Moreover, companies that design flexible business models for distribution-balancing offline channel relationships with growing online procurement-can better navigate regional differences in purchasing behavior and logistics requirements. Ultimately, success hinges on aligning product portfolios with technical expectations across ELISA, immunofluorescence, and PCR platforms while addressing sample type preferences and user capabilities.

Practical strategic actions for diagnostic leaders to strengthen supply chain resilience, validate clinical performance, and align products with diverse care settings and user needs

Industry leaders should prioritize a set of pragmatic actions to translate diagnostic science into sustained clinical impact and commercial viability. First, strengthen supply chain resilience by diversifying component sourcing and negotiating flexible contracts that accommodate tariff-driven variability and logistics disruptions. Second, invest in validation partnerships with academic institutes and hospital laboratories to generate independent performance evidence across key sample types such as nasopharyngeal swab and saliva, and to demonstrate clinical utility across adult, geriatric, and pediatric cohorts. These partnerships will help accelerate clinical acceptance and inform reimbursement discussions.

Third, design product bundles that interoperate across instruments, kits, and reagents; compatibility reduces procurement friction for diagnostic laboratories and hospital networks. Fourth, tailor commercialization strategies to regional nuances, leveraging hybrid distribution approaches that combine offline channel strength with online procurement efficiency. Fifth, advance user-centered rapid test formats for clinics and home care, while supporting centralized laboratories with high-throughput molecular solutions. Finally, embed digital result reporting and data analytics into test offerings to support clinicians, public health surveillance, and post-market performance monitoring. Together, these actions will strengthen clinical relevance and long-term resilience.

Transparent multi-source methodology combining literature synthesis, regulatory review, technical validation, and stakeholder interviews to deliver rigorous diagnostic insights and segmentation clarity

This research synthesizes peer-reviewed literature, regulatory filings, clinical guidance documents, product technical specifications, and primary stakeholder interviews to construct a multi-dimensional view of RSV diagnostics. The methodology combined systematic review of recent scientific publications and technical white papers with structured interviews of laboratory directors, clinical end users, and industry subject matter experts. The analysis prioritized cross-validation of technical claims against independently reported performance data and real-world implementation feedback.

Segmentation frameworks were developed to capture the interplay among test type, product, technology platform, end user, sample type, distribution channel, and age group, enabling granular insight into where diagnostic performance and adoption risk converge. Regional analyses integrated policy and procurement context to account for operational realities across the Americas, Europe Middle East & Africa, and Asia-Pacific. The approach emphasizes transparent assumptions, documented sources for technical parameters, and an evidence-led narrative designed to support strategic decision-making by diagnostics manufacturers, laboratory leaders, and clinical stakeholders.

Synthesis of diagnostic technology strengths, operational imperatives, and strategic priorities that together determine lasting clinical and commercial success in RSV testing

In conclusion, the landscape of RSV diagnostics is defined by a dynamic balance between technological capability and real-world usability. Molecular, immunoassay, and rapid formats each contribute distinct strengths to clinical pathways, and their convergence creates opportunities to improve patient outcomes through more timely and accurate detection. Supply chain and trade developments have underscored the need for resilient sourcing and flexible operational planning, while regional and end-user heterogeneity demands tailored approaches to product design and commercialization.

Decision-makers should therefore pursue integrated strategies that link robust technical validation with pragmatic deployment planning, including partnerships with clinical and academic stakeholders. By aligning instrument ecosystems, kits, and reagents with user requirements across hospital laboratories, diagnostic labs, clinics, and home care settings, organizations can enhance diagnostic impact. Ultimately, the most effective strategies will be those that combine technical excellence with adaptability to regulatory, procurement, and operational realities across regions and patient cohorts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid expansion of point-of-care molecular testing for RSV enabling decentralized patient management and faster treatment decisions
  • 5.2. Integration of multiplex respiratory panels combining RSV, influenza, and SARS-CoV-2 detection for comprehensive seasonal virus surveillance
  • 5.3. Adoption of isothermal amplification technologies in RSV diagnostics driving improved sensitivity and reduced turnaround time in outpatient settings
  • 5.4. Increasing demand for home-based RSV testing kits supported by telehealth platforms and remote patient monitoring solutions
  • 5.5. Growing focus on pediatric and neonatal RSV screening protocols in hospitals to reduce severe infection rates and optimize resource allocation
  • 5.6. Emergence of digital health and AI-driven interpretation tools enhancing the accuracy and workflow efficiency of RSV diagnostic laboratories
  • 5.7. Regulatory approvals for next generation sequencing assays targeting RSV genetic subtyping and antiviral resistance profiling in clinical trials
  • 5.8. Impact of shifting RSV seasonality patterns post-COVID-19 pandemic on testing volumes and public health surveillance strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RSV Diagnostics Market, by Test Type

  • 8.1. Immunoassay
    • 8.1.1. Chemiluminescence Immunoassay
    • 8.1.2. Enzyme Linked Immunosorbent Assay
    • 8.1.3. Immunofluorescence Assay
  • 8.2. Molecular Test
    • 8.2.1. Isothermal Amplification
    • 8.2.2. Next Generation Sequencing
    • 8.2.3. Real Time Polymerase Chain Reaction
  • 8.3. Rapid Test
    • 8.3.1. Lateral Flow Assay
    • 8.3.2. Microfluidic Assay

9. RSV Diagnostics Market, by Product

  • 9.1. Instruments
    • 9.1.1. Analyzers
    • 9.1.2. PCR Machines
  • 9.2. Kits
    • 9.2.1. Saliva Collection Kits
    • 9.2.2. Swab Collection Kits
  • 9.3. Reagents
    • 9.3.1. Buffers
    • 9.3.2. Enzymes

10. RSV Diagnostics Market, by Technology Platform

  • 10.1. ELISA
  • 10.2. Immunofluorescence
  • 10.3. PCR

11. RSV Diagnostics Market, by End User

  • 11.1. Academic Institutes
  • 11.2. Clinics
  • 11.3. Diagnostic Laboratories
  • 11.4. Home Care
  • 11.5. Hospital Laboratories

12. RSV Diagnostics Market, by Sample Type

  • 12.1. Blood
  • 12.2. Nasopharyngeal Swab
  • 12.3. Saliva

13. RSV Diagnostics Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. RSV Diagnostics Market, by Age Group

  • 14.1. Adult
  • 14.2. Geriatric
  • 14.3. Pediatric

15. RSV Diagnostics Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. RSV Diagnostics Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. RSV Diagnostics Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Abbott Laboratories
    • 18.3.2. Roche Diagnostics International AG
    • 18.3.3. QuidelOrtho Corporation
    • 18.3.4. Thermo Fisher Scientific Inc.
    • 18.3.5. bioMerieux SA
    • 18.3.6. Becton, Dickinson and Company
    • 18.3.7. Danaher Corporation
    • 18.3.8. Meridian Bioscience, Inc.
    • 18.3.9. DiaSorin S.p.A.
    • 18.3.10. QIAGEN N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RSV DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. RSV DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. RSV DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RSV DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RSV DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RSV DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY MICROFLUIDIC ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA COLLECTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SWAB COLLECTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BUFFERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOFLUORESCENCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL RSV DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY KITS, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 332. LATIN AMERICA RSV DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPE, MIDDLE EAST & AFRICA RSV DIAGNOSTICS MARKET